214 related articles for article (PubMed ID: 19842939)
1. Pharmacogenetics of tenofovir treatment.
Rodriguez-Novoa S; Labarga P; Soriano V
Pharmacogenomics; 2009 Oct; 10(10):1675-85. PubMed ID: 19842939
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Giacomet V; Cattaneo D; Viganò A; Nannini P; Manfredini V; Ramponi G; Clementi E; Zuccotti GV
Pediatr Infect Dis J; 2013 Oct; 32(10):e403-5. PubMed ID: 24067562
[TBL] [Abstract][Full Text] [Related]
3. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Rodríguez-Nóvoa S; Labarga P; Soriano V; Egan D; Albalater M; Morello J; Cuenca L; González-Pardo G; Khoo S; Back D; Owen A
Clin Infect Dis; 2009 Jun; 48(11):e108-16. PubMed ID: 19400747
[TBL] [Abstract][Full Text] [Related]
4. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Kinai E; Hanabusa H
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Ezinga M; Wetzels JF; Bosch ME; van der Ven AJ; Burger DM
Antivir Ther; 2014; 19(8):765-71. PubMed ID: 24584104
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
7. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
[TBL] [Abstract][Full Text] [Related]
8. Renal tubular dysfunction associated with tenofovir therapy.
Mitra S; Priscilla R; Rajeev K; Sauradeep S; Rajkumar S; Cherian AO
J Assoc Physicians India; 2014 Jul; 62(7):580-2. PubMed ID: 25672029
[TBL] [Abstract][Full Text] [Related]
9. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Dahlin A; Wittwer M; de la Cruz M; Woo JM; Bam R; Scharen-Guivel V; Flaherty J; Ray AS; Cihlar T; Gupta SK; Giacomini KM
Pharmacogenet Genomics; 2015 Feb; 25(2):82-92. PubMed ID: 25485598
[TBL] [Abstract][Full Text] [Related]
10. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
Labarga P; Barreiro P; Martin-Carbonero L; Rodriguez-Novoa S; Solera C; Medrano J; Rivas P; Albalater M; Blanco F; Moreno V; Vispo E; Soriano V
AIDS; 2009 Mar; 23(6):689-96. PubMed ID: 19262355
[TBL] [Abstract][Full Text] [Related]
11. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Gatanaga H; Tachikawa N; Kikuchi Y; Teruya K; Genka I; Honda M; Tanuma J; Yazaki H; Ueda A; Kimura S; Oka S
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):744-8. PubMed ID: 16910829
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
13. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Uglietti A; Zanaboni D; Gnarini M; Maserati R
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Prescrire Int; 2014 May; 23(149):124-5. PubMed ID: 24926511
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
[TBL] [Abstract][Full Text] [Related]
16. An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
Danjuma MI; Mohamad-Fadzillah NH; Khoo S
Int J STD AIDS; 2014 Mar; 25(4):273-9. PubMed ID: 24067251
[TBL] [Abstract][Full Text] [Related]
17. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
[TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Bickel M; Khaykin P; Stephan C; Schmidt K; Buettner M; Amann K; Lutz T; Gute P; Haberl A; Geiger H; Brodt HR; Jung O
HIV Med; 2013 Nov; 14(10):633-8. PubMed ID: 23980564
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir-induced osteomalacia.
Wanner DP; Tyndall A; Walker UA
Clin Exp Rheumatol; 2009; 27(6):1001-3. PubMed ID: 20149322
[TBL] [Abstract][Full Text] [Related]
20. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Stephan C
Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
